



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: September 14, 2007

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The attached Pathology Reporting Form has been revised as follows:

- Histologic Subtype “(check all that apply; for mixed tumors, specify by prevalence in comments):” has been changed to “(number all that apply; for mixed tumors, specify by prevalence):”
- Line added to the “Signatures” box at the bottom of the form to collect “Block/Slide number(s) to be used for research/banking.”

The following password will need to be used to open up the Investigator Brochure – RTOG Cancer Group

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure